Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular
- Fundraising led by Cambrian BioPharma and Solve FSHD -- Company expands pipeline with new program, VTA-120, for the treatment of facioscapulohumeral muscular dystrophy (FSHD) -BALTIMORE--(BUSINESS WIRE)--Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop novel cellular therap...
Source: pharmiweb.com